title: A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.
authors.affiliation: a Department of Hematology and Medical Oncology , Emory University - Winship Cancer Institute , Atlanta , GA , USA.
authors.forename: Jonathon B
authors.initials: JB
authors.lastname: Cohen
authors.affiliation: b Division of Hematology , The Ohio State University James Comprehensive Cancer Center , Columbus , OH , USA.
authors.forename: Kami J
authors.initials: KJ
authors.lastname: Maddocks
authors.affiliation: b Division of Hematology , The Ohio State University James Comprehensive Cancer Center , Columbus , OH , USA.
authors.forename: Ying
authors.initials: Y
authors.lastname: Huang
authors.affiliation: b Division of Hematology , The Ohio State University James Comprehensive Cancer Center , Columbus , OH , USA.
authors.forename: Beth A
authors.initials: BA
authors.lastname: Christian
authors.affiliation: b Division of Hematology , The Ohio State University James Comprehensive Cancer Center , Columbus , OH , USA.
authors.forename: Samantha M
authors.initials: SM
authors.lastname: Jaglowski
authors.affiliation: a Department of Hematology and Medical Oncology , Emory University - Winship Cancer Institute , Atlanta , GA , USA.
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Flowers
authors.affiliation: b Division of Hematology , The Ohio State University James Comprehensive Cancer Center , Columbus , OH , USA.
authors.forename: Kristie A
authors.initials: KA
authors.lastname: Blum
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001381:Azepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000473:pathology*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D019233:Retreatment; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001381:Azepines; C550258:MLN 8237; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines